2 results
Approved WMOWill not start
To compare the progression-free survival (PFS) in subjects with pancreatic islet cell tumors treated with sunitinib at a starting dose of 37.5 mg daily (continuous dosing) with those treated with placebo.
Approved WMORecruiting
The primary objective of the study is determine the effect of an 8-week standardized exercise training program in patients with persistent functional limitations 4 weeks after a diagnosis of acute PE, on physical performance (as assessed by the…